Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Gross Profit
Interpace Biosciences Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Gross Profit
$23.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
0%
|
|
DaVita Inc
NYSE:DVA
|
Gross Profit
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Gross Profit
$3.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
CVS Health Corp
NYSE:CVS
|
Gross Profit
$53.6B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
Cigna Corp
NYSE:CI
|
Gross Profit
$25.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Gross Profit
$3.4B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
See Also
What is Interpace Biosciences Inc's Gross Profit?
Gross Profit
23.9m
USD
Based on the financial report for Dec 31, 2023, Interpace Biosciences Inc's Gross Profit amounts to 23.9m USD.
What is Interpace Biosciences Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
0%
Over the last year, the Gross Profit growth was 31%. The average annual Gross Profit growth rates for Interpace Biosciences Inc have been 31% over the past three years , 15% over the past five years .